报价延迟最少15分钟:2025/11/07 18:37 EST
盘后时段
|
||||
|
2.08 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.03
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.16/-0.05
|
|
企业价值
32.70M
|
| 资产负债 |
|
每股账面净值
1.86
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
66.38M
|
|
每股收益
10.54
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/11/07 18:37 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties. |
